Featured SARMs Series: Molecular Optimization and Pharmacokinetic Enhancement
In the field of SARMs research, molecular structure optimization is a key pathway to enhancing compound performance and applicability. RAD150 (an esterified variant of RAD140) and ACP-105 represent two classes of structurally modified featured compounds. The former improves pharmacokinetic properties through an esterification strategy, while the latter stands out for its high selectivity in muscle and prostate safety studies. PHMO is committed to providing these scientifically optimized research tools to help researchers conduct more precise mechanistic exploration and model development.
As SARMs research deepens, structural optimization of foundational compounds has become an important direction for expanding their research value. By introducing ester groups, adjusting substituents, or optimizing stereochemistry on the parent molecule, researchers can improve a compound's solubility, half-life, tissue selectivity, or metabolic stability. RAD150 and ACP-105 are exemplary of such optimization designs; they not only retain the core activity of their prototype compounds but also demonstrate enhanced utility in specific research scenarios. This product series is strictly limited to scientific research and is not suitable for human or clinical use.
1. Function & Core Research Applications
l RAD150 (CAS: 1208070-53-4)
A benzoate-derived non-steroidal SARM, it is an esterified variant of RAD140 with high affinity (IC50=130nM). Preclinical studies show that by prolonging half-life and enhancing stability, it promotes selective activation of muscle tissue. It is primarily used in research on lean muscle mass gain, strength improvement, and physical performance. In animal models, it supports long-term dosing regimens and reverses muscle loss, although a human dose is not established and is for research reference only.
l ACP-105 (CAS: 899821-23-9)
An oral non-steroidal SARM with potency comparable to testosterone in vitro assays (with no interaction with other hormone receptors). Research focuses on muscle mass increase, bone density maintenance, and neuroprotection. In Alzheimer's disease mouse models, it reduces anxiety-like behavior and improves spatial memory. It is mainly used in animal model research for muscle atrophy, osteoporosis, and neurodegenerative diseases. Preclinical data indicates it can reverse markers of testosterone deficiency, such as muscle and bone degeneration, without significantly affecting other hormonal axes.
Note: Products supplied by PHMO are for in vitro or preclinical research use only. Not for human use.
2. Differentiating Features & Advantages
Compared to standard SARMs (e.g., RAD140), these featured compounds are optimized at the molecular level to enhance pharmacokinetics and multifunctionality. RAD150, through its esterification design, extends half-life and stability, reducing the need for frequent dosing, which distinguishes it from the rapid metabolism of its parent compound RAD140. ACP-105 uniquely integrates neuroprotective mechanisms, making it more suitable for brain-muscle axis research compared to other SARMs (e.g., the LGD series focusing on bone and muscle). Both possess excellent oral bioavailability, reduce hepatotoxicity and hormone-related side effects, making research data more reliable and closer to clinical translation.
3. Target Audience & Market Validation
These compounds target pharmaceutical R&D personnel, nutritional scientists, and academic laboratories for exploring the molecular mechanisms of muscle metabolism optimization, neuroprotection, and metabolic diseases. Market validation is based on preclinical animal studies (e.g., RAD150's muscle performance enhancement and ACP-105's neurobehavioral improvement). Although not yet entered into human trials, they are widely used as optimized tools within the scientific community. The global SARMs market is projected to continue strong growth, especially in personalized medicine and elderly health sectors, but it is emphasized that they are for research only, not consumer products. By supplying these molecularly optimized compounds, PHMO demonstrates its professional understanding of cutting-edge SARMs design.
Exploring the frontier of molecularly optimized SARMs begins with high-quality research materials. PHMO ensures that every batch of featured compound products comes with a detailed Certificate of Analysis (COA) to guarantee the accuracy and reliability of your research data. Contact us for a quotation, or comment below to share your research needs. PHMO – Your Reliable Research Partner!